by CheckRare Staff | Jan 23, 2023
Adeline Vanderver, MD, Program Director of the Leukodystrophy Center in the Division of Neurology at Children’s Hospital of Philadelphia (CHOP), provides an overview of the different types of clinical trials that are underway to treat individuals with...
by CheckRare Staff | Jan 19, 2023
Alok Tayi, PhD, Founder and CEO of Vibe Bio, gives an overview of his company, its mission and objectives, and how it plans to advance the development of rare disease therapies. As Dr. Tayi explains, he founded Vibe Bio after his daughter was hospitalized at...
by CheckRare Staff | Jan 18, 2023
Donald Zoz, MD, Director and Senior Clinical Program Leader for Pulmonary Fibrosis at Boehringer Ingelheim provides an overview of idiopathic pulmonary fibrosis (IPF) and how to diagnose this rare condition. IPF is a chronic, progressive, fibrosing lung disease...
by CheckRare Staff | Jan 17, 2023
Gerard Vockley, MD, PhD, Head of the Division of Medical Genetics at UPMC Children’s Hospital of Pittsburgh, discusses new data testing a probiotic to treat individuals with phenylketonuria (PKU). PKU is a rare genetic metabolic disorder that results in...
by CheckRare Staff | Jan 16, 2023
Adam Lamble, MD, Attending Physician, Cancer and Blood Disorders Center, Seattle Children’s Hospital, discusses a recent study that lists six high-risk alterations of acute myeloid leukemia (AML) that ought to be included in Children’s Oncology Group’s...
